Why the study?
Frailty occurs in up to 50% of HF patients and is an important, potentially reversible prognostic marker in advanced HF, highlighting the need to understand its measurement, mechanisms, and role across cardiovascular cohorts.
Frailty is a dynamic and potentially reversible condition present in up to 50% of heart failure patients, making its serial measurement crucial for prognostication and determining therapy benefits.
Frailty is a complex, multi-system condition often associated with multimorbidity. It has become an important prognostic maker across a range of conditions and is particularly relevant in patients with cardiovascular disease. Frailty encompasses a range of domains including, physical, psychological, and social. There are currently a range of validated tools available to measure frailty. It is an especially important measurement in advanced HF, because frailty occurs in up to 50% of HF patients and is potentially reversible with therapies such as mechanical circulatory support and transplantation. Moreover, frailty is dynamic, and therefore serial measurements are important. This review delves into the measurement of frailty, mechanisms, and its role in different cardiovascular cohorts. Understanding frailty will help determine patients that will benefit from therapies, as well as prognosticate outcomes.
No takes yet. Share an insight, caveat, or question.
Bart et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: